November 28, 2023
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability
Prioritizing metastatic non-small cell lung cancer launch and focusing research and development activities in areas of greatest anticipated value creation Expected reduction in residual operating expenses of approximately $60 million, including a reduction in headcount of approximately 200 colleagues, 13% of total workforce ROOT, Switzerland–(BUSINESS… Read More
learn more
November 21, 2023
Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference
ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that management will participate in the 35th Annual Piper Sandler Healthcare Conference on Wednesday, November 29, 2023. William Doyle, Novocure’s Executive Chairman, and Ashley Cordova, Novocure’s Chief Financial Officer, will take part in a fireside chat at 3:30 p.m. EST, as… Read More
learn more
November 10, 2023
Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting
ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced that research on Tumor Treating Fields (TTFields) therapy, including new data from the phase 2 2-THE-TOP trial and real-world evidence from patients diagnosed with glioblastoma (GBM) and other central nervous system tumors (CNS), will be presented at the 2023 Society for… Read More
learn more